Progress in the field of precision medicine has changed the landscape of cancer therapy.
Precision medicine is propelled by technologies that enable molecular profiling, genomic …

Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …

Abstract Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently
mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with …

Cancer genomics studies have identified thousands of putative cancer driver genes.
Development of high-throughput and accurate models to define the functions of these genes …

The immunosuppressive protein PD-L1 is upregulated in many cancers and contributes to
evasion of the host immune system. The relative importance of the tumor microenvironment …

Profiling candidate therapeutics with limited cancer models during preclinical development
hinders predictions of clinical efficacy and identifying factors that underlie heterogeneous …

Purpose: KRAS is among the most commonly mutated oncogene in cancer including non–
small cell lung cancer (NSCLC). In early clinical trials, inhibitors targeting G12C-mutant …

KRAS gain-of-function mutations occur in approximately 30% of all human cancers. Despite
more than 30 years of KRAS-focused research and development efforts, no targeted therapy …

Non-small-cell lung cancers (NSCLCs), the most common lung cancers, are known to have
diverse pathological features. During the past decade, in-depth analyses of lung cancer …

Identifying genetic alterations that prime a cancer cell to respond to a particular therapeutic
agent can facilitate the development of precision cancer medicines. Cancer cell-line (CCL) …